InteKrin Therapeutics, Inc.
http://www.intekrin.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From InteKrin Therapeutics, Inc.
BIO Notebook: Amgen CEO Blasts IRA, Novo Nordisk Stays Cautious On BD, And More
Insights from Day Three of the BIO International Convention in San Diego include Amgen CEO Bob Bradway taking aim at the "Innovation Reduction Act," Novo Nordisk's business development head talking about spending its semaglutide bounty, Roivant's long view on BD prospects for Immunovant's FcRn inhibitor, and more regulatory concerns around artificial intelligence.
BIO Notebook: Amgen CEO Blasts IRA, Novo Nordisk Stays Cautious On BD, And More
Insights from Day Three of the BIO International Convention in San Diego include Amgen CEO Bob Bradway taking aim at the "Innovation Reduction Act," Novo Nordisk's business development head talking about spending its semaglutide bounty, Roivant's long view on BD prospects for Immunovant's FcRn inhibitor, and more regulatory concerns around artificial intelligence.
BIO Notebook: Dealing With Rejection, Worrying About March-In Rights, And More
Insights from the first day of the international convention in San Diego also includes interviews on Alzheimer’s investments, dealmaking for mid-sized companies and reflections on the virtues of lean thinking.
BIO Notebook: Dealing With Rejection, Worrying About March-In Rights, And More
Insights from the first day of the international convention in San Diego also includes interviews on Alzheimer’s investments, dealmaking for mid-sized companies and reflections on the virtues of lean thinking.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice